Fístula anal o fisura

Undecylenic acid is an unsaturated C11 fatty acid derived from castor oil with recognized antifungal activity against Candida. It prevents the yeast-to-hyphal morphological transition critical to Candida pathogenesis and disrupts biofilms. It has FDA recognition as an OTC antifungal active ingredient and is a standard component of natural Candida support formulas.

Ajoene has demonstrated potent in vitro antifungal activity against Candida albicans and other fungi at concentrations below 20 µg/mL. Clinical trials in humans have shown efficacy against dermatophytoses (tinea pedis, tinea cruris, tinea corporis), with 1% topical ajoene achieving 100% mycologic cure rates comparable to terbinafine. Its mechanism involves disruption of fungal phospholipid biosynthesis and membrane integrity.

In vitro studies demonstrate that ajwain essential oil and its active constituents thymol and carvacrol inhibit Candida albicans growth. Laboratory studies have documented antifungal activity blocking 72–90% of fungal growth across multiple species. No human clinical trials exist, but the in vitro evidence is scientifically documented.

Allicin is garlic's primary bioactive antifungal compound, with documented anti-Candida activity comparable to fluconazole in vitro. It disrupts Candida cell membranes and biofilms and inhibits hyphal transition. It is among the most well-researched natural antifungal compounds and is referenced in professional Candida protocols.

In vitro studies confirm P. dioica essential oil inhibits Candida albicans. Lorenzo-Leal et al. (2019, PMC) tested allspice EO against Candida albicans and reported MIC-based inhibitory activity. Eugenol's antifungal properties are well established in the literature.

In vitro studies show A. galanga extracts inhibit Candida albicans, Candida tropicalis, and Candida glabrata. The antifungal diterpene (E)-8β,17-epoxylabd-12-ene-15,16-dial and acetoxychavicol acetate (ACA) are identified as key active compounds. Evidence is limited to laboratory and preclinical data; no human trials exist.

In vitro studies demonstrate ACV inhibits Candida albicans growth, requiring undiluted (5% acidity) concentration for full antifungal effect. A 2018 PubMed study confirmed antifungal activity at full strength but noted yeasts including Candida are less susceptible than bacteria. No robust human RCTs for internal Candida treatment exist.

In vitro studies using berberine from Berberis vulgaris demonstrate significant antifungal activity against Candida albicans and other Candida species, including fluconazole-resistant strains. Berberine disrupts fungal membrane integrity, inhibits biofilm formation, and reverses multidrug resistance. Human clinical data are limited; evidence is primarily in vitro.

Bee propolis has documented in vitro antifungal activity against Candida albicans and other Candida species confirmed across multiple geographic sources. It inhibits germ tube formation and hyphal growth—key Candida virulence factors. Multiple peer-reviewed studies and integrative Candida protocols support its use for Candida and yeast balance.

Berberine, an isoquinoline alkaloid from plants including barberry and goldenseal, shows documented antifungal activity against multiple Candida species in vitro, including fluconazole-resistant strains. It disrupts Candida membranes, inhibits biofilm formation, and inhibits C. albicans adhesion to vaginal epithelial cells in clinical mechanistic studies. Preclinical evidence is extensive though human Candida-specific RCTs remain limited.

Hydroxychavicol, the principal phenol of betel leaf, exhibits concentration-dependent antifungal activity against Candida albicans and other Candida species, including clinical isolates and biofilms. In vitro studies demonstrate MIC values in clinically relevant ranges and disruption of fungal cell membranes.

Black seed (Nigella sativa) contains thymoquinone, which has documented fungicidal activity against Candida species including drug-resistant C. glabrata—a WHO high-priority pathogen. It induces Candida cell death via oxidative stress and inhibits Candida biofilm gene expression. Both traditional and in vitro scientific evidence support its use for Candida balance.

Multiple laboratory studies demonstrate that juglone and black walnut hull extracts inhibit Candida albicans growth and biofilm formation. In vitro studies have established MIC values and shown activity against fluconazole-resistant strains. This is supported by traditional use of black walnut as an antifungal for intestinal and vaginal yeast overgrowth.

A 2020 in vitro study (PMC7803126) demonstrated that Thai cajuput oil exhibits fungicidal activity against fluconazole-resistant Candida albicans clinical isolates, with MICs of 0.31–1.25 µl/ml and the ability to downregulate MDR1 efflux-pump gene expression. Earlier studies showed cajuput oil inhibits growth of C. albicans, C. vaginalis, C. glabrata, Aspergillus niger, and Penicillium notatum at 0.4–0.6% concentration. All evidence is in vitro; no human clinical trials exist.

Multiple in vitro studies confirm calendula's antifungal activity against Candida species, with antifungal potency comparable to nystatin against oral Candida strains. The ESCOP monograph cites controlled clinical use for vaginal candidiasis. Both topical and internal preparations have been investigated.

Caprylic acid is an eight-carbon medium-chain fatty acid from coconut oil that disrupts the lipid membranes of Candida cells, causing cell death and inhibiting hyphal growth and biofilm formation in vitro. Multiple laboratory studies confirm antifungal activity against C. albicans. A pediatric RCT found MCT supplementation (including caprylic acid) reduced Candida gastrointestinal colonization in preterm infants.

Carvacrol, the dominant phenolic compound in oregano oil, shows the strongest antifungal activity of any botanical compound against Candida albicans in comparative MIC studies. It disrupts cell membranes, inhibits biofilms, and acts synergistically with caprylic acid for a 6-log reduction of C. albicans. Multiple peer-reviewed studies confirm its potency.

Cassia bark essential oil demonstrates potent in vitro antifungal activity against Candida albicans and other Candida species, including fluconazole-resistant strains. One small clinical study in HIV patients with oral candidiasis reported improvement in 3 of 5 subjects using cinnamon candy lozenges for one week. C. cassia is identified among the most promising essential oil sources for oral candidiasis in systematic reviews of the literature.

Cinnamon bark extract and its key compound cinnamaldehyde demonstrate potent antifungal activity against multiple Candida species, including drug-resistant strains, via cell wall disruption. Preliminary human data exist for oral and vaginal candidiasis. One double-blind RCT found oral cinnamon capsule superior to clotrimazole vaginal cream for candidal vaginitis treatment and recurrence.

Multiple in vitro studies and a 2023 PMC systematic review confirm that clove essential oil and eugenol inhibit Candida species, including fluconazole-resistant strains, through ergosterol binding and biofilm disruption. Evidence covers oral and vaginal candidiasis models.

In vitro studies demonstrate that VCO's MCFAs (lauric acid, caprylic acid) inhibit Candida albicans at measurable MIC values, with activity comparable to ketoconazole in one study. A murine dietary study showed coconut oil reduced GI C. albicans colonization versus beef tallow. Clinical human data remain limited to indirect measures and in vitro models.

Lauric acid and caprylic acid—the key medium-chain fatty acids in coconut milk—have demonstrated anticandidal activity in vitro, disrupting Candida albicans cell membranes and inhibiting biofilm formation. In vitro studies show inhibition zones comparable to standard antifungal drugs. Human clinical evidence is limited but in vitro and mechanistic data are robust.

Coconut oil's medium-chain fatty acids—particularly caprylic, capric, and lauric acids—have documented antifungal activity against Candida in multiple in vitro and animal studies. A randomized clinical trial found it comparable to fluconazole for oral Candida. MCT supplementation from coconut oil reduced Candida gastrointestinal colonization in a pediatric RCT.

Berberine from Coptis chinensis shows demonstrated antifungal activity against Candida albicans in multiple in vitro and microbiological studies, including against fluconazole-resistant strains. The mechanism involves disruption of the HOG-MAPK pathway, impairment of cell wall integrity, and inhibition of biofilm formation. Clinical human data remain limited.

Curcumin, the principal polyphenol of turmeric, demonstrates antifungal activity against multiple Candida strains including nystatin-resistant and fluconazole-resistant isolates. Multiple in vitro studies confirm MIC activity against C. albicans, biofilm inhibition, and reduction of virulence factor secretion. It synergizes with standard antifungals.

Echinacea extracts demonstrate in vitro antifungal activity against Candida species, with alkamides identified as the primary active constituents disrupting fungal cell wall integrity. A 2010 Oxford/Medical Mycology study used genome-wide yeast deletion arrays to show the fungal cell wall as the target of Echinacea. Limited early clinical data (Lasch et al., 1983) suggested E. purpurea reduced recurrence of candidiasis when added to standard antifungal therapy, but no modern RCTs have confirmed this.

Alantolactone, the principal sesquiterpene lactone of elecampane, has demonstrated antifungal activity against Candida albicans and other Candida species in published in vitro studies. Mechanisms include disruption of cell membrane integrity, inhibition of biofilm formation, and induction of reactive oxygen species. All evidence is preclinical.

In vitro studies show that aqueous and alcoholic extracts of asafoetida inhibit Candida albicans growth, though MIC values are higher than standard antifungal drugs. Asafoetida also inhibits Aspergillus flavus. Activity is attributed to its organosulfur compounds, coumarins, and flavonoids.

Garlic contains allicin, a sulfur compound with well-documented antifungal activity against Candida albicans. A randomized controlled trial found garlic extract tablets to be approximately as effective as fluconazole for vaginal yeast infections. Multiple in vitro studies confirm inhibition of Candida growth, hyphal formation, and biofilm disruption.

Garlic's allicin and ajoene demonstrate dose-dependent antifungal activity against Candida albicans and related yeasts in in vitro and some clinical settings. Allicin inhibits fungal metabolic enzymes and biofilm formation. Evidence is strongest from in vitro and animal studies; human clinical trials are limited.

Multiple in vitro studies demonstrate complete inhibition of Candida albicans by geranium EO. Studies also confirm activity against C. tropicalis, C. glabrata, and C. krusei. The antifungal mechanism involves disruption of yeast cell membranes by terpenoids.

A double-blind randomized controlled trial (n=66, Prêcheur et al., Antibiotics, 2020) demonstrated that a fluorinated toothpaste containing S. virgaurea extract significantly reduced oral Candida albicans biofilm in healthy adults compared to placebo. In vitro studies confirm that goldenrod extract inhibits Candida adherence, hyphal formation, and biofilm biomass. Saponins are the primary active constituents.

Goldenseal (Hydrastis canadensis) is a berberine-rich North American medicinal herb with documented antifungal activity via its primary alkaloid berberine. Multiple peer-reviewed studies confirm berberine's anti-Candida mechanisms including membrane disruption, biofilm inhibition, and adhesion blocking. It has been used in North American herbal medicine for mucosal Candida infections for centuries.

Hemicellulase (particularly its glucanase activity) can hydrolyze beta-glucans and other polysaccharides in the Candida albicans cell wall, mechanistically disrupting its structural integrity. In vitro evidence shows this activity degrades Candida biofilm and exposes fungal antigens to immune surveillance. Human clinical trials specifically isolating hemicellulase for Candida are lacking, but the mechanistic basis is grounded in published mycology research.

In vitro studies show that Hibiscus sabdariffa extract inhibits Candida albicans biofilm formation, hyphae initiation, and adherence, including fluconazole-resistant strains. Fungistatic activity has been demonstrated with MIC values of 0.5–2.0 mg/mL. Evidence is currently limited to in vitro and preclinical models with no published human clinical trials.

Linalool from Cinnamomum genera has demonstrated fungicidal activity against fluconazole-resistant Candida albicans strains in vitro, disrupting cell wall and membrane integrity. Ho wood is also traditionally used to 'combat fungal infections of the skin.'

Multiple in vitro studies demonstrate fungicidal activity of horseradish essential oil and ITCs against Candida albicans. Horseradish ITCs inhibited C. albicans in standardised antimicrobial assays alongside other oral and pathogenic microorganisms. Evidence is entirely in vitro; no clinical trials for systemic or mucosal Candida.

Hyssop essential oil and extracts have demonstrated antifungal activity against Candida albicans and other fungal pathogens in multiple in vitro studies. A 2025 PMC study on Hyssopus cuspidatus volatile extract showed inhibition of C. albicans biofilm formation and hyphal development, including against fluconazole-resistant strains.

Lactobacillus acidophilus has demonstrated inhibitory activity against Candida species in clinical and laboratory studies. A 2024 comprehensive review of 25 clinical studies identified it as one of the most evidenced strains for managing vulvovaginal candidiasis. It inhibits Candida pathogenic potential in vaginal epithelial cell models and is used as adjuvant therapy in clinical Candida protocols.

L. crispatus produces lactic acid, hydrogen peroxide, and antimicrobial peptides that inhibit Candida albicans growth and block the yeast-to-hyphae transition critical for virulence. In vitro studies show it reduces C. albicans adhesion to vaginal epithelial cells by ~42–53%. A 2025 randomized placebo-controlled trial of a multi-strain L. crispatus vaginal synbiotic demonstrated significant reduction of Candida alongside restoration of a healthy vaginal microbiome. Animal model data further support antifungal efficacy.

Lactobacillus fermentum has demonstrated inhibitory activity against both Candida albicans and C. glabrata. It is identified in a 2024 comprehensive review of 25 clinical studies as an evidence-supported strain for vulvovaginal candidiasis management. A clinical strain isolated from human throat showed growth inhibition of both major Candida species.

L. gasseri is a dominant commensal in the healthy vaginal microbiome and has demonstrated direct anti-Candida activity in in vitro and mechanistic studies. It forms mixed biofilms with Candida albicans and C. glabrata resulting in pronounced yeast cell death, and produces biosurfactants that inhibit Candida adhesion. Clinical research supports oral L. gasseri supplementation for restoring vaginal flora.

L. jensenii is documented to produce lactic acid and hydrogen peroxide, creating an acidic vaginal environment hostile to Candida albicans overgrowth. In vitro research demonstrates it co-aggregates with Candida species and produces antifungal compounds. It is recognized as one of the dominant protective species in the healthy vaginal community, where its presence correlates with reduced yeast colonization.

Lactobacillus plantarum has demonstrated inhibitory activity against Candida parapsilosis and C. albicans in vaginal epithelial cell models. It is identified in a 2024 comprehensive review of 25 clinical studies as an evidence-supported strain for VVC management, and in vitro studies confirm its anti-Candida cell-free supernatant activity.

Lactobacillus reuteri RC-14 has strong clinical evidence for Candida inhibition, with an RCT demonstrating reductions in vaginal yeast colonization. In vitro studies confirm potent candidacidal activity against C. glabrata, and a 2024 review of 25 clinical studies identifies it as a consistently evidenced strain for VVC management. It colonizes the vaginal tract when taken orally.

Lactobacillus rhamnosus GR-1 is among the most clinically validated probiotic strains for Candida inhibition. An RCT demonstrated significant reductions in vaginal yeast colonization. In vitro studies confirm potent candidacidal activity and biofilm disruption against C. glabrata, and it is identified in a 2024 review of 25 clinical studies as a top evidence-supported strain for VVC management.

Lactoferrin exhibits documented antifungal activity against multiple Candida species through iron sequestration and membrane disruption. Systematic review and meta-analysis confirm inhibition of both azole-susceptible and azole-resistant C. albicans. Lactoferrin also acts synergistically with standard antifungals including fluconazole and amphotericin B.

In vitro studies demonstrate that the LPO system exhibits direct anti-Candida activity. LPO-generated oxidants (hypothiocyanite and hypoiodite) inhibit Candida albicans growth, biofilm formation, and metabolic activity. Synergistic candidacidal effects are observed when LPO is combined with lactoferrin. Clinical human trials specifically for Candida balance with LPO supplementation are not yet established; evidence is currently preclinical.

Multiple in vitro studies demonstrate that lavender essential oil exhibits both fungistatic and fungicidal activity against Candida albicans, including inhibiting hyphal elongation and germ tube formation. A 2005 Oxford Academic study showed 100% killing of C. albicans within 15 minutes at 2% concentration. Lavender oil has also shown synergistic enhancement of fluconazole's antifungal activity.

LGEO shows consistent in vitro antifungal activity against Candida albicans and related species, attributed to citral disrupting fungal cell membranes. A 2014 study found LGEO produced large inhibition zones against C. albicans and C. tropicalis. A tissue-conditioner study confirmed anti-Candida efficacy at low MIC values. Evidence is predominantly laboratory-based with limited human clinical trials.

Licorice root extract demonstrates antifungal activity against Candida albicans in vitro and in preclinical animal models of gastrointestinal candidiasis. A 2022 murine study showed oral licorice root extract significantly reduced C. albicans fecal counts and GI colonization. Clinical human trials are lacking; evidence is currently preclinical.

Limonene shows well-documented in vitro antifungal activity against multiple Candida species, including drug-resistant strains. It disrupts Candida biofilm formation, cell membrane integrity, and morphogenesis. In vivo murine intravaginal candidiasis models confirm protective effects. Evidence is preclinical; no human clinical trials have been conducted for candidiasis specifically.

Mangosteen xanthones demonstrate in vitro antifungal activity including against Candida species. Traditional use for thrush (oral candidiasis) is documented in Southeast Asian medicine. The PMC mechanistic review lists Candida glabrata among organisms studied against mangosteen compounds. No human clinical trials for candidiasis have been conducted.

Caprylic acid (C8) and capric acid (C10), the primary components of MCT oil, have demonstrated antifungal activity against Candida species in vitro and in some clinical settings. One human study found MCT supplementation reduced Candida colonization in the GI tracts of preterm infants.

Melaleuca alternifolia (tea tree) oil has documented antifungal activity against azole-susceptible and azole-resistant Candida species in vitro and in animal models of vaginal candidiasis. Its constituent terpinen-4-ol is the primary antifungal agent, acting via membrane disruption. In vivo studies confirm it accelerates Candida clearance from vaginal tissue in rat models.

In vitro studies show peppermint oil has antifungal activity against Candida species, with some studies showing stronger activity than the commercial antifungal bifonazole. Menthol and other terpenes are the proposed active components. Human clinical evidence for Candida treatment is limited to in vitro and animal data.

Monolaurin (glycerol monolaurate) is derived from lauric acid in coconut oil with documented in vitro antifungal activity against Candida albicans. Laboratory studies show it can reduce C. albicans growth by 99% in minutes via membrane disruption. It is used in integrative Candida protocols, often combined with undecylenic acid, and is noted for selective targeting of pathogens over beneficial microorganisms.

A. vulgaris essential oil has demonstrated significant antifungal activity against Candida albicans in laboratory disc-diffusion assays, with inhibition zones exceeding those of standard antifungals such as ketoconazole. Antifungal activity is attributed to 1,8-cineole, α-thujone, and camphene. Evidence is in vitro only; no human clinical trials exist.

Myristoleic acid has been identified in vitro as one of three fatty acids most active at inhibiting Candida albicans germination, based on research on cheese by-product fatty acids. This is in vitro evidence only, derived from the free acid form of the myristoleate moiety.

Multiple laboratory studies confirm myrrh's antifungal activity against pathogenic Candida species including C. albicans, C. tropicalis, C. guilliermondii, and C. neoformans. Specific sesquiterpenes (curzerene, β-elemene) and the essential oil fraction show MIC-level inhibition of C. albicans. No human clinical trials for Candida infection exist.

Multiple in vitro and dental studies confirm neem extracts inhibit Candida albicans growth and adhesion. A PMC study found aqueous neem extract suppresses C. albicans colonisation of denture surfaces. The Frontiers in Pharmacology review (2022) lists Candida among fungal species susceptible to A. indica compounds. Human clinical trials for systemic or mucosal candidiasis are absent.

Anti-Candida activity of C. rotundus is documented in the PMC 2018 review and other sources. The essential oil and extracts show inhibitory activity against Candida species in vitro, contributing to the plant's documented antifungal profile.

OA has documented antifungal activity including against Candida species in preclinical studies, and is listed in multiple pharmacological reviews as having antimicrobial and antifungal properties. This activity is noted alongside its antibacterial and antiparasitic effects.

Oleuropein, the primary bioactive polyphenol in olive leaf extract, has documented in vitro antifungal activity against Candida albicans and other clinical Candida species. It inhibits C. albicans filamentation (a key virulence factor), reduces cellular adhesion, and induces apoptotic cell death. Multiple peer-reviewed in vitro studies confirm dose-dependent anti-Candida activity.

Oregano essential oil, standardized for carvacrol and thymol, consistently shows potent antifungal activity against Candida albicans in laboratory studies and against clinical Candida isolates including fluconazole-resistant strains. Carvacrol disrupts Candida cell membranes and inhibits virulence factors. It is a primary antifungal in clinical integrative Candida protocols.

Berberine and jatrorrhizine from Mahonia aquifolium demonstrate in vitro antifungal activity against multiple Candida species, including fluconazole-resistant strains. The 2004 Slobodníková study tested M. aquifolium extract directly against Candida isolates from vulvovaginal candidiasis. Evidence is currently limited to in vitro; no clinical trials using Oregon grape specifically for candida infections in humans have been published.

Pau d'arco inner bark is a traditional South American remedy used for centuries for yeast and fungal infections. It contains naphthoquinones lapachol and beta-lapachone with documented antifungal activity against C. albicans and C. tropicalis in vitro. Evidence is primarily laboratory-based with strong traditional support.

P. amurense methanol extract significantly inhibited the growth of numerous Candida species in vitro, with berberine and palmatine as the predominant active agents. Berberine has been demonstrated to inhibit fluconazole-resistant Candida strains and Candida biofilm formation in vitro. Berberine inhibits Candida adhesion to vaginal epithelial cells through immunological mechanisms. TCM also uses P. amurense for gynaecological candida infections.

Pomegranate peel extract and its active polyphenols (particularly punicalagin, ellagic acid) exhibit documented antifungal activity against Candida albicans and other Candida species in vitro, and some clinical studies have evaluated pomegranate mouthwash for oral candidiasis. Activity likely involves disruption of fungal membrane integrity.

A 2005 in vitro study (Bafi-Yeboa et al., Phytomedicine 12[5]:370-7) demonstrated that all Zanthoxylum americanum extracts showed broad-spectrum antifungal activity against 11 strains including Candida albicans, inhibiting at least 8 fungal species. Antifungal activity was positively correlated (r²=0.902, p<0.001) with furanocoumarin content. Evidence is in vitro only with no human clinical trials.

Propolis is a resinous hive product from bees with broad-spectrum antifungal activity against multiple Candida species confirmed across multiple in vitro studies from diverse geographic sources. It inhibits C. albicans germ tube formation and growth. Multiple reviews confirm consistent anti-Candida activity, and it is recognized in integrative Candida protocols.

Radish contains a defensin protein, RsAFP2, which has been shown in vitro and in murine models to induce apoptosis in Candida albicans via cell wall disruption and ceramide accumulation. In vitro activity has been confirmed against multiple Candida species, though Candida glabrata is resistant. No human clinical trials have been conducted.

Saccharomyces boulardii is a non-pathogenic probiotic yeast with the strongest clinical evidence among probiotics for inhibiting Candida colonization. Clinical studies confirm significant reductions in vaginal yeast colonization, and it is the only commercially available probiotic yeast with evidence for Candida inhibition. Multiple mechanisms including Candida virulence inhibition are documented.

S. flavescens extract demonstrates in vitro antifungal activity against multiple Candida species including drug-resistant strains. Phytochemical screening has identified flavonoids and alkaloids as active antifungal agents. One human case report documents S. flavescens use for vulvovaginal candidiasis.

A. muricata extracts demonstrate antifungal activity against Candida albicans, including multi-drug resistant strains, in vitro. The activity is attributed to acetogenins and alkaloids disrupting fungal cell envelope integrity.

Tea tree oil (Melaleuca alternifolia) and its primary constituent terpinen-4-ol show potent antifungal activity against both azole-susceptible and azole-resistant Candida species in vitro and in animal models of vaginal candidiasis. In vivo animal studies demonstrate accelerated clearance of C. albicans from vaginal tissue. It is used topically in complementary medicine for Candida-related conditions.

T. chebula methanol extracts have demonstrated antifungal activity against Candida albicans (including clotrimazole-resistant strains) in vitro. T. catappa extracts were tested against Candida biofilms on denture materials in a laboratory study. Traditional use against oral candidiasis is documented. Activity is attributed to hydrolyzable tannins and gallic acid.

Thyme essential oil (TEO), principally via thymol, exerts well-documented fungistatic and fungicidal activity against Candida albicans and other Candida species in laboratory and preclinical studies. It has shown efficacy against fluconazole-resistant clinical isolates, inhibiting germ tube formation and biofilm development. Evidence is currently in vitro and animal-based; clinical human trials are lacking.

Thymus vulgaris essential oil and its constituent thymol exhibit documented antifungal activity against Candida species in multiple in vitro studies, including inhibition of C. albicans germ tube formation and biofilm disruption. Thymol and carvacrol act synergistically with antifungal drugs against drug-resistant Candida strains. Evidence is predominantly in vitro; clinical trials in humans with candidiasis are lacking.

In vitro and in vivo (Galleria mellonella) studies demonstrate pterostilbene exerts direct fungicidal effects against Candida albicans and Candida dubliniensis, disrupting biofilm formation. Complete inhibition of viability was observed at 32 µg/mL within 8 hours of exposure. No human clinical trials have been conducted.

Turmeric (Curcuma longa) and its active curcuminoids demonstrate antifungal properties against Candida albicans in multiple in vitro studies, including activity against drug-resistant strains. Turmeric inhibits Candida biofilm formation and modulates virulence factors. Traditional Ayurvedic use for fungal and infectious conditions spans thousands of years.

Antifungal activity of Zanthoxylum extracts against Candida species is documented in multiple laboratory studies. Z. zanthoxyloides extract showed significant activity against Candida albicans in in vitro assays. Several isolated coumarins and alkaloids from Zanthoxylum have documented antifungal mechanisms.

Buchu has a documented traditional use against yeast (Candida) infections, particularly as a vaginal douche and internal remedy. Its essential oil and leaf extracts show antimicrobial and antifungal properties in vitro, though no clinical trials in humans have validated this use.

Cellulase is traditionally used in candida-cleanse supplement protocols on the theory that it can disrupt the cellulose-containing components of Candida cell walls or biofilms. An in vitro study (2006, Institute of Biomedical and Life Sciences, Glasgow) found that cellulase and glucoamylase partially detached Candida albicans biofilms from plastic surfaces. However, Wikipedia's analysis of the Candex supplement notes that cellulase is generally not active on chitin, the primary structural component of yeast cell walls, and no peer-reviewed human clinical evidence supports a direct anti-Candida effect from oral cellulase supplementation.

Cranberry PACs have been shown in vitro to inhibit Candida albicans adhesion, biofilm formation, and virulence gene expression. These mechanisms are biologically plausible, but no human clinical trials have established clinical efficacy for Candida infections. The relationship is currently supported by in vitro evidence and the broader traditional use of cranberry in urogenital health.

Molybdenum is used in functional medicine circles for Candida support based on the role of aldehyde oxidase in breaking down acetaldehyde, a toxic metabolite produced by Candida albicans overgrowth. No controlled clinical trials have evaluated molybdenum supplementation for Candida outcomes directly. The rationale is plausible biochemically but remains anecdotal and traditional in its evidence base.